Drugs / Human Milk Oligosaccharides
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06102213 | Sep 2023 → Aug 2024 | hematopoietic and lymphoid cell neoplasm | Prolacta Bioscience | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-05-03 | Prolacta Bioscience | Results Study published in the journal Cell Host & Microbe offers proof of concept that a human milk-based synbiotic could allow therapeutic manipulation of the gut microbiome prolacta.com ↗
In the publication “Dosing a Synbiotic of Human Milk Oligosaccharides and B. infantis Leads to Reversible Engraftment in Healthy Adult Microbiomes Without Antibiotics,” scientists report that in healthy adult subjects, simultaneous ingestion of a combination of human milk-derived HMOs and B. infantis results in high-level, controllable, HMO-dependent engraftment of B. infantis . |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-03 | Prolacta Bioscience | Study published in the journal Cell Host & Microbe offers proof of concept that a human milk-based synbiotic could allow therapeutic manipulation of the gut microbiome prolacta.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Milk Oligosaccharides | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06102213 ↗ |
| Known as | HMO | “PBCLN-010: Human Milk Oligosaccharides (HMO).” NCT06102213 ↗ |
| Route | Oral | “HMO will be administered at 9.0 g orally twice a day (BID)” NCT06102213 ↗ |